VXRT News and Press, Vaxart Inc. From 06/02/22

Investors ought to be even more careful where they put their money in times like these. It's more important than ever to make highly selective investment decisions with a struggling stock market, challenging economic issues, and dangerous geopolitical tensions. Sure, many companies that...

Results support safety and immunogenicity of the vaccine candidate in the highly vulnerable elderly population Preliminary boost study data also reported Norovirus has been estimated to cost the United States $10.6 billion annually SOUTH SAN FRANCISCO, Calif., June...

SOUTH SAN FRANCISCO, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Andrei Floroiu, President and Chief Executive Officer, Dr. Sean Tucker, SVP and Chief Scientific Officer, and Dr. James Cummings, Chief Medical Officer, will participate in a fire...

A preclinical study in hamsters showed both a decrease in infectious virus and in transmission Phase 1 data measuring cross-reactivity also included in the publication SOUTH SAN FRANCISCO, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Science Translational Medicine ha...

Vaxart (NASDAQ: VXRT) has been involved in the coronavirus vaccine race since the beginning. It's developing what could be a game-changing option: a vaccine in pill form. That's why this biotech player has been one to watch. That potential product is now involved in phase 2 stud...

Vaxart (NASDAQ:VXRT) announced that it is retaining Fuad Ahmad, a partner at FLG, a CFO services and board advisory consulting firm, as its interim CFO and a non-employee consultant. The company is conducting its search for a CFO. As of May 10, 2022, Andrei Floroiu ceased to serve a...

Upstart Holdings (UPST) -54% on Q1 earnings release. GoodRx Holdings (GDRX) -35% on Q1 earnings release. Bausch Health Companies (BHC) -33% on Q1 earnings release. Peloton Interactive (PTON) -24% on FQ3 earnings release. Novavax (NVAX) -2...

Vaxart press release (NASDAQ:VXRT): Q1 GAAP EPS of -$0.20 misses by $0.04. Revenue of $0.09M (-82.4% Y/Y) misses by $0.04M. Cash, equivalents and available-for-sale debt securities of $157.0 million, compared to $182.7 million as of December 31, 2021. The decrease was primarily...

Data from COVID-19 Phase II study and norovirus Phase IB study are expected in 2022 Ended the 1 st Quarter with $157.0 million in cash, cash equivalents and marketable securities SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Decelerating momentum and limited profitability prospects make these stocks analysts hate. Bed Bath & Beyond ( BBBY ): The meme stock continues to burn cash due to supply chain problems. Netflix ...